Drug Approval | February 13, 2025
FDA approves Pfizer’s ADCETRIS combination regimen for the treatment of Relapsed/Refractory DLBCL
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Approval is based on positive data from the Phase 3 ECHELON-3 trial
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
He has over 23 years of experience across sectors
_256_384.jpg)
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
TFOS is indicated for the treatment of pulmonary arterial hypertension
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Subscribe To Our Newsletter & Stay Updated
